Drugs / ZL-1201
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04257617 | May 2020 → May 2022 | — | Zai Lab (Shanghai) Co., Ltd. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2022-04-06 | Zai Lab (Shanghai) Co., Ltd. | Results Zai Lab to Present New Oncology Research at 2022 AACR Annual Meeting zailaboratory.com ↗
The CD47-targeting antibody ZL-1201 enhances anti-tumor activity of standard of care therapeutic antibodies by promoting phagocytosis in hematologic and solid tumor models |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2022-04-06 | Zai Lab (Shanghai) Co., Ltd. | Zai Lab to Present New Oncology Research at 2022 AACR Annual Meeting zailaboratory.com ↗ |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ZL-1201 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04257617 ↗ |